Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
BYDUREON EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk
Based on a composite measure of major adverse CV events (MACE), Bydureon did not increase cardiovascular (CV) risk and showed a consistent safety profile
Fewer events were observed in the Bydureon arm, however, the efficacy objective of reduction in CV risk did not reach statistical significance
Phase III ZONDA trial for benralizumab shows ability to reduce oral steroid use in severe asthma patients
Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo
Benralizumab also reduced overall exacerbation rates by 70% and exacerbations requiring emergency room visits or hospitalizations by 93% in patients with severe, uncontrolled eosinophilic asthma
Trial results simultaneously published in New England Journal of Medicine
IMFINZI™ (durvalumab) significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer
Durvalumab met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis
Durvalumab is the first immuno-oncology medicine to show superior PFS in this setting
Plans for regulatory submission under active discussion with authorities
AstraZeneca’s IMFINZI™ (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer
Approval granted regardless of PD-L1 status, based on tumor response rate and duration of response
IMFINZI is the cornerstone in an extensive Immuno-Oncology program across multiple cancer types and stages of disease
Latest AZ&You Blog Articles
Knowing Your Options When Facing Advanced Bladder Cancer
Two and a half years ago, retired singer and musician Phil Esser learned he had advanced stage bladder cancer. We wanted to bring Phil’s experience, which he generously shared with us, to those who may have been affected by this disease or want to better understand living with advanced bladder cancer.
Advancing Science and Accelerating Innovation in the BioHealth Capital Region
Collaboration across academia, government, non-profits, and the biopharmaceutical industry fosters innovation and groundbreaking discoveries in science and research. During the 2017 BioHealth Capital Region (BHCR) Forum held at our Gaithersburg, Maryland campus, world-renowned speakers and local leaders convened to showcase the benefits of continued collaboration that can help us prevent, treat, and find cures for deadly diseases.
Supporting Patients and Communities: Our 2016 Corporate Responsibility at a Glance
Everything we do at AstraZeneca is driven by our commitment to improving the lives of patients, and part of that involves our corporate responsibility efforts to support healthy, vibrant communities beyond our medicines.
A New Approach to Reducing Lung Cancer Deaths and Extending Lives
Important developments are under way that provide increased hope for those at high risk for lung cancer. For the first time ever, leading health care, nonprofit, government and for-profit groups are coming together for a concerted effort around lung cancer screening, representing a huge shift in how we fight lung cancer, the leading cause of cancer death in the United States.
The Power of Us: Employees’ Community Impact in 2016
AstraZeneca has a long history of community service and a strong commitment to making a meaningful difference for patients and communities beyond our medicines through our corporate responsibility activities. In addition to our corporate efforts, our Power of Us program empowers employees to give back in two ways: by providing paid time off to volunteer with nonprofit organizations of their choice, as well as by matching their charitable donations.
Our Favorites from 2016 – Highlights of the AZ&You Blog
Throughout 2016 on our blog, we shared interviews with patients; news about partnerships and initiatives that help support patients and science; stories that illustrate our focus on advancing patient health and access to care; and much more. From the dozens of blog posts we published this year, we put together a list of some of our favorites that we want to make sure you catch before the year is over.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.